Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics, is pleased to announce the appointment of Magnus Gustafsson as Chief Commercial Officer (CCO).
Magnus brings an exceptional wealth of experience from global roles across the pharma, biotech and CDMO industries. His proven expertise in building and leading commercial teams will be vital as NorthX expands its reach, particularly in new markets like North America.
Magnus holds an MSc in biotechnology from the Royal Institute of Technology, a PhD in Medical Biochemistry and Biophysics from Karolinska Institute and an MBA from Stockholm Business School.
Janet Hoogstraate, CEO NorthX Biologics comments: “I am delighted to welcome Magnus to the team as we continue our growth journey. His impressive credentials and experience will be invaluable to both the leadership team and the business.”
Magnus Gustafsson adds: “NorthX Biologics offers an impressive range of services, from microbial and mammalian recombinant proteins to viral products, mRNA, plasmids, cell therapy, and exosomes. The company’s reputation as a trusted partner, with satisfied clients and expert staff, makes it an exciting time to join. I look forward to working with the team to support our clients in delivering life-changing therapies to patients worldwide.”
Media inquiries
Please contact Janet Hoogstraate, CEO, janet.hoogstraate@nxbio.com
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development, and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity ...
Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Johanna Magnusson as Chief Operating Officer. With over two decades of leadership experience in ...
NorthX Biologics, a leading biopharmaceutical CDMO, has been officially accredited by the French Ministry of Higher Education and Research for the Crédit d’Impôt Recherche (CIR) program for the years 2025-2026. ...